UB Paderborn / Katalog / Suche / in CDI

1 – 23 von 23

Sortiert nach

Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin‐Based Chemotherapy for Muscle‐Invasive Bladder Cancer

The oncologist (Dayton, Ohio), 2019-05, Vol.24 (5), p.688-690

2019

Volltextzugriff (PDF)

Does histologic subtype impact overall survival in observed T1a kidney cancers compared with competing risks? Implications for biopsy as a risk stratification tool

International journal of urology, 2022-08, Vol.29 (8), p.845-851

2022

Volltextzugriff (PDF)

A Systematic Review of Systemic Treatment Options for Advanced Non-Clear Cell Renal Cell Carcinoma

Kidney cancer, 2020-01, Vol.4 (1), p.15-27

2020

Volltextzugriff (PDF)

Association Between Symptomatic Versus Asymptomatic Recurrence and Survival in Bladder Cancer

Clinical genitourinary cancer, 2018-06, Vol.16 (3), p.235-239

2018

Volltextzugriff (PDF)

Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer

Journal of clinical oncology, 2021-10, Vol.39 (28), p.3140-3148

2021

Volltextzugriff (PDF)

Searching for the perfect combination of drug, disease, genetic alteration, and screening test to maximize FGFR inhibition in urothelial cancer

Cancer, 2020-06, Vol.126 (11), p.2588-2591

2020

Volltextzugriff (PDF)

Impairment and Longitudinal Recovery of Older Adults Treated with Radical Cystectomy for Muscle Invasive Bladder Cancer

The Journal of urology, 2021-01, Vol.205 (1), p.94

2021

Volltextzugriff (PDF)

Risk stratification and outreach to hematology/oncology patients during the COVID-19 pandemic

Supportive care in cancer, 2021-03, Vol.29 (3), p.1161-1164

2021

Volltextzugriff (PDF)

New and Emerging Therapies in the Management of Bladder Cancer [version 1; peer review: 2 approved]

F1000 research, 2020, Vol.9, p.1146

2020

Volltextzugriff (PDF)

Predictive Modeling for Adverse Events and Risk Stratification Programs for People Receiving Cancer Treatment

JCO oncology practice, 2022-02, Vol.18 (2), p.127-136

2022

Volltextzugriff (PDF)

Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma

Kidney cancer, 2020-09, Vol.4 (3), p.131-137

2020

Volltextzugriff (PDF)

The association between functional impairment pre- and post-cystectomy with neoadjuvant chemotherapy use in patients with muscle-invasive bladder cancer

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e17008-e17008

2020

Volltextzugriff (PDF)

Functional outcomes of older adults treated with radical cystectomy for muscle-invasive bladder cancer

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e17010-e17010

2020

Volltextzugriff (PDF)

A pilot study of risk stratification and outreach to hematology/oncology patients during the COVID-19 pandemic

Journal of clinical oncology, 2020-10, Vol.38 (29_suppl), p.211-211

2020

Volltextzugriff (PDF)

The association of malnutrition and sarcopenia with geriatric assessment impairment and outcomes in patients with bladder cancer undergoing cystectomy

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.423-423

2021

Volltextzugriff (PDF)

Differences in survival between symptomatic versus asymptomatic recurrence following cystectomy for bladder cancer

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e16021-e16021

2017

Volltextzugriff (PDF)

Efficacy of enfortumab vedotin in advanced urothelial cancer: Retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.443-443

2021

Volltextzugriff (PDF)

Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy prior to radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC)

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.396-396

2021

Volltextzugriff (PDF)

Efficacy of split schedule (SS) vs conventional schedule (CS) neoadjuvant cisplatin-based chemotherapy for muscle-invasive bladder cancer (MIBC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.4545-4545

2018

Volltextzugriff (PDF)

Molecular Imaging Modalities: Applications of Current and Novel Radiotracers

Comprehensive Diagnostic Approach to Bladder Cancer, 2021, p.115-136

2021

Volltextzugriff (PDF)

Overall Survival of Biopsy-confirmed T1B and T2A Kidney Cancers Managed With Observation: Prognostic Value of Tumor Histology

Clinical genitourinary cancer, 2021-08, Vol.19 (4), p.280-287

2021

Volltextzugriff (PDF)

Problems in Hand Surgery: Solutions to Recover Function

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(21)

Publikationsform

Sprache

Englisch
(22)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin‐Based Chemotherapy for Muscle‐Invasive Bladder Cancer

Does histologic subtype impact overall survival in observed T1a kidney cancers compared with competing risks? Implications for biopsy as a risk stratification tool

A Systematic Review of Systemic Treatment Options for Advanced Non-Clear Cell Renal Cell Carcinoma

Association Between Symptomatic Versus Asymptomatic Recurrence and Survival in Bladder Cancer

Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer

Searching for the perfect combination of drug, disease, genetic alteration, and screening test to maximize FGFR inhibition in urothelial cancer

Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study

Impairment and Longitudinal Recovery of Older Adults Treated with Radical Cystectomy for Muscle Invasive Bladder Cancer

Risk stratification and outreach to hematology/oncology patients during the COVID-19 pandemic

New and Emerging Therapies in the Management of Bladder Cancer [version 1; peer review: 2 approved]

Predictive Modeling for Adverse Events and Risk Stratification Programs for People Receiving Cancer Treatment

Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma

The association between functional impairment pre- and post-cystectomy with neoadjuvant chemotherapy use in patients with muscle-invasive bladder cancer

Functional outcomes of older adults treated with radical cystectomy for muscle-invasive bladder cancer

A pilot study of risk stratification and outreach to hematology/oncology patients during the COVID-19 pandemic

The association of malnutrition and sarcopenia with geriatric assessment impairment and outcomes in patients with bladder cancer undergoing cystectomy

Differences in survival between symptomatic versus asymptomatic recurrence following cystectomy for bladder cancer

Efficacy of enfortumab vedotin in advanced urothelial cancer: Retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study

Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy prior to radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC)

Efficacy of split schedule (SS) vs conventional schedule (CS) neoadjuvant cisplatin-based chemotherapy for muscle-invasive bladder cancer (MIBC)

Molecular Imaging Modalities: Applications of Current and Novel Radiotracers

Overall Survival of Biopsy-confirmed T1B and T2A Kidney Cancers Managed With Observation: Prognostic Value of Tumor Histology

Problems in Hand Surgery: Solutions to Recover Function

Suchergebnisse filtern